---
title: "\"Performance\" LUXXU GROUP's annual loss narrowed to 21.687 million RMB"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281106838.md"
description: "LUXXU GROUP announced its performance for the fiscal year 2025, with revenue of 42.07 million yuan (same below), an increase of 43.2% year-on-year. Losses narrowed to 21.687 million yuan, compared to a loss of 51.964 million yuan in the same period last year; loss per share was 12.19 cents. No dividend was declared"
datetime: "2026-03-31T01:40:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281106838.md)
  - [en](https://longbridge.com/en/news/281106838.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281106838.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/281106838.md) | [繁體中文](https://longbridge.com/zh-HK/news/281106838.md)


# "Performance" LUXXU GROUP's annual loss narrowed to 21.687 million RMB

LUXXU GROUP (01327.HK) announced its 2025 annual results, with revenue of RMB 42.07 million, an increase of 43.2% year-on-year. Losses narrowed to RMB 21.687 million, compared to a loss of RMB 51.964 million in the same period last year; loss per share was 12.19 cents. No dividend was declared

### Related Stocks

- [LUXXU GROUP (01327.HK)](https://longbridge.com/en/quote/01327.HK.md)

## Related News & Research

- [Luxxu Group Sets Board Meeting to Approve 2025 Results and Mull Final Dividend](https://longbridge.com/en/news/278713264.md)
- [A Look At Fosun International (SEHK:656) Valuation After Recent Mixed Share Price Performance](https://longbridge.com/en/news/281035263.md)
- [Fosun Pharmaceutical to Set Up Parallel Fund Structure](https://longbridge.com/en/news/281297569.md)
- [Osl Group FY adjusted non-IFRS income HK$534.1 million](https://longbridge.com/en/news/281223382.md)
- [CICC Sticks to Its Buy Rating for C&D International Investment Group Ltd. (1908)](https://longbridge.com/en/news/280899096.md)